Tirzepatide
Cross-source consensus on Tirzepatide from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Risks & contraindications
Comparisons
Highlighted claims
- Tirzepatide is the first approved dual GIP/GLP-1 receptor agonist. — GLP-1 Medications: A Comprehensive Clinical Guide
- Tirzepatide (Zepbound) achieves approximately 12–20% weight loss when used for weight management in adults. — GLP-1 Medications: A Comprehensive Clinical Guide
- Tirzepatide (Mounjaro) achieves a 1.7–2.3% reduction in A1C for type 2 diabetes. — GLP-1 Medications: A Comprehensive Clinical Guide
- Patients who discontinue tirzepatide after a run-in period regain substantial weight compared to those who continue treatment. — GLP-1 Medications: A Comprehensive Clinical Guide